Inotuzumab ozogamicin following allogeneic hematopoietic stem cell transplantation successfully rescued relapse of CD19-negative acute lymphoblastic leukemia after CAR-T cell therapy

摘要

Anti-CD19 chimeric antigen receptor (CAR)-T-cell therapy is one of the most promising treatment options for patients with relapsed/refractory B-cell precursor (BCP)-acute lymphoblastic leukemia (ALL). Approximately 30%-60% of patients experience relapse after CAR-T cell therapy, largely due to poor longevity of CAR-T cells and loss or downregulation of CD19 expression by leukemic cells.4,5 The survival rate of these patients is extremely poor; however, there is no consensus regarding the best salvage treatment.